Flexeril (cyclobenzaprine) is not classified as a controlled substance by the DEA, and it carries a lower addiction risk than opioids or benzodiazepines. But it can become habit-forming, particularly when used at higher doses, for longer than recommended, or alongside other substances. The FDA approves Flexeril for short-term use only, up to two or three weeks, partly because the risk of dependence and misuse increases with extended use.
How Flexeril Works in the Brain
Flexeril is a centrally acting muscle relaxant, meaning it works in your brain and spinal cord rather than directly on muscles. Structurally, it is closely related to tricyclic antidepressants. It primarily acts in the brain stem, where it reduces the signals that keep muscles in a constant state of tension. It also blocks certain serotonin receptors, which contributes to its antispasmodic effect.
This brain-level activity is what makes Flexeril effective for muscle spasms, but it’s also what gives the drug its sedating, relaxing quality. At recreational doses (20 to 80 milligrams, well above the typical prescribed range), cyclobenzaprine can produce significant drowsiness, deep relaxation, and a sense of euphoria. That pleasurable effect is what drives misuse. Researchers have linked the drug’s potential for addictive behavior to its impact on the brain’s reward system.
What the Misuse Data Shows
A large-scale analysis of FDA adverse event reports found 179 cases of drug abuse linked to cyclobenzaprine, with a reporting odds ratio over 17 times higher than the background rate across all drugs. That’s a strong signal. The same database showed 96 reports of overdose and 57 reports of intentional overdose. These numbers don’t mean Flexeril is as dangerous as an opioid, but they do show that misuse is a real and documented pattern, not a theoretical risk.
Notably, drug abuse was identified as a potential adverse reaction not even listed on the drug’s original label. It emerged from post-market surveillance data, meaning the full scope of misuse wasn’t apparent during the drug’s initial approval process.
Why the Three-Week Limit Matters
The FDA label is explicit: Flexeril should not be used for more than two to three weeks. The reasoning is twofold. First, there’s no evidence that the drug remains effective beyond that window. Second, the muscle spasms it’s designed to treat are typically short-lived, so prolonged therapy is rarely needed.
Using Flexeril beyond this recommended period increases your exposure to side effects that compound over time. Because the drug blocks certain receptors in the nervous system (the same ones affected by tricyclic antidepressants), extended use can lead to dry mouth, confusion, rapid heartbeat, urinary retention, and even hallucinations. Your body can also begin to adjust to the drug’s sedating effects, which means you may feel like you need a higher dose to get the same relief. That cycle of tolerance and dose escalation is a hallmark of habituation.
Physical Dependence vs. Psychological Habituation
Flexeril dependence tends to develop along two tracks. Physical dependence means your body has adapted to the drug’s presence and reacts when it’s removed. Psychological habituation means you feel anxious or uncomfortable without it, or you begin relying on the sedation to sleep or manage stress rather than using it strictly for muscle pain.
People who take Flexeril nightly for sleep, for example, sometimes find it difficult to stop because they’ve come to associate the drug with their ability to relax. This kind of habituation can develop even at prescribed doses if use continues long enough. The drowsiness and calm that Flexeril produces can feel necessary over time, even when the original muscle spasm has resolved.
What Happens When You Stop
Flexeril does not produce the dramatic, dangerous withdrawal seen with alcohol or benzodiazepines. But stopping abruptly after regular use can cause discomfort. Case reports describe neuropsychiatric side effects during use, including psychosis and involuntary muscle movements, that resolved within 48 hours of discontinuation. The relationship between symptom onset and drug exposure, followed by resolution when the drug was stopped, points to a direct effect of cyclobenzaprine on the nervous system.
If you’ve been taking Flexeril for longer than the recommended window, tapering off gradually rather than stopping all at once is a safer approach. Rebound muscle tension, difficulty sleeping, and irritability are commonly reported by people who discontinue after extended use.
Dangerous Combinations That Raise the Risk
Flexeril’s habit-forming potential increases significantly when combined with other substances that slow down the central nervous system. The drug is already a sedative on its own. Adding alcohol, opioids, benzodiazepines, or sleep medications on top of it doesn’t just double the sedation; it can multiply it unpredictably.
Combining Flexeril with alcohol can cause severe drowsiness, dangerously slow breathing, loss of coordination, and in some cases, coma or death. The same applies to opioid combinations, which carry the added risk of respiratory depression. People who misuse Flexeril recreationally often combine it with other depressants to intensify the high, which is where the overdose risk becomes most serious.
Even prescribed combinations can be problematic. If you’re taking an opioid for pain and Flexeril for spasms at the same time, the sedative effects stack. Barbiturates and benzodiazepines carry the same compounding risk.
Why It’s Not a Controlled Substance
Flexeril’s legal status can be misleading. Because the DEA does not classify cyclobenzaprine as a controlled substance, many people assume it’s completely safe and non-addictive. In practice, its lack of scheduling means prescribers face fewer restrictions when writing refills, and patients may not treat it with the same caution they’d give a medication that comes with a controlled substance warning.
The drug’s chemical similarity to tricyclic antidepressants, its documented effect on the brain’s reward pathways, and the FDA’s adverse event data all suggest that the risk of habit formation is genuine, even if it falls below the threshold that triggers DEA scheduling. Treating Flexeril as a short-term tool for acute muscle spasms, exactly as the label recommends, is the most reliable way to avoid dependence.